Actinium Pharmaceuticals, Inc. has entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc., under which Goodwin will oversee cGMP production of Iomab-B, a monoclonal antibody for an upcoming Phase III trial in patients preparing for bone marrow transplant.   “This agreement with Goodwin represents a major risk mitigation step in conducting our Phase III trial of Iomab-B,” said Kaushik J. Dave, president and chief executive officer of Actinium. “Goodwin has significant expe...